Replies to post #22696 on BioCurex, Inc.(fka BOCX)

[HALF FULL GLASS]

Do those drums sound like this?

Lots of news today, so let's get to it.
BioCurex (OTC BB: BOCX): Your Questions Answered

My little $.07 idea from last week has turned into a barn burner. Little known and treacherously speculative BOCX, which I published on last week at $.07, is now $.22- no big deal- $.08? Consider it's more than a triple in one week.

Just the beginning of the resurgence for this highly speculative and treacherous little stock. This is one of those situations where the stock has been so blown out it could trade up more rather easily.

I wanted to clarify one major issue. Many of you have been emailing me- asking me if the company has an FDA approval for it's highly sensitive cancer test. The answer is both yes and no.

What they have is an FDA exemption- anotherwords, they don't need an approval, for a version of their test for tissue samples. However, the commercial market is looking for a blood test version, and they will have to go through an FDA study to get it. It won't be anything like an FDA approval for a new drug- probably just a six month test to prove it works.



After all, they are not puttting anything in the body, and they are not treating anybody. They are just trying to commercialize a technology that will allow them participate in the single most important factor in cancer therapy- early detection.

There was news today- lest you worry about them having money, they just completed a small private placement for $400,000- this is a low overhead operation, so that money will go a long way. Click here if you want to read the news.

Here's a bit of a longer term chart. I provide this so you can get the big picture. The stock has turned up, but look where it's come from over the past year. Down from $.50.

And yes, both Abbot Labs (NYSE: ABT), and Inverness Medical (NYSE: IMA) have signed on and licensed their technology.

Short term price target: $.30.- that's about 66% higher than today's levels.